Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003

PURPOSE: We hypothesized that bevacizumab will potentiate activity of pembrolizumab. We conducted a phase Ib/II, single-arm, multisite clinical trial of the combination in metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients with metastatic clear cell RCC who experienced progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudek, Arkadiusz Z., Liu, Li C., Gupta, Shilpa, Logan, Theodore F., Singer, Eric A., Joshi, Monika, Zakharia, Yousef N., Lang, Joshua M., Schwarz, James K., Al-Janadi, Anas, Alva, Ajjai S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145584/
https://www.ncbi.nlm.nih.gov/pubmed/32097091
http://dx.doi.org/10.1200/JCO.19.02394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145584/
https://www.ncbi.nlm.nih.gov/pubmed/32097091
http://dx.doi.org/10.1200/JCO.19.02394

Ejemplares similares